DNA origami vaccines program antigen-focused germinal centers
Authors:
- Anna RomanovARAnna Romanov
- Grant A. KnappeGKGrant A. Knappe
- Larance RonsardLRLarance Ronsard
- Heikyung SuhHSHeikyung Suh
- Marjan OmerMOMarjan Omer
- Asheley P. ChapmanACAsheley P. Chapman
- Vanessa R. LewisVLVanessa R. Lewis
- Katie SpivakovskyKSKatie Spivakovsky
- Boris ReizisBRBoris Reizis
- Ryan D. TingleRTRyan D. Tingle
- Christopher A. CottrellCCChristopher A. Cottrell
Preprint
Abstract
Recruitment and expansion of rare precursor B cells in germinal centers (GCs) is a central goal of vaccination to generate broadly neutralizing antibodies (bnAbs) against challenging pathogens such as HIV. Multivalent immunogen display is a well-established method to enhance vaccine-induced B cell responses, typically accomplished by using natural or engineered protein scaffolds. However, these scaffolds themselves are targets of antibody responses, with the potential to generate competitor scaffold-specific B cells that could theoretically limit expansion and maturation of “on-target” B cells in the GC response. Here, we rationally designed T-independent, DNA-origami based virus-like particles (VLPs) with optimal antigenic display of the germline targeting HIV Env immunogen, eOD-GT8, and appropriate T cell help to achieve a potent GC response. In preclinical mouse models, these DNA-VLPs expanded significantly higher frequencies of epitope-specific GC B cells compared with a state-of-the-art clinical protein nanoparticle. Optimized DNA-VLPs primed germinal centers focused on the target antigen and rapidly expanded subdominant broadly neutralizing antibody precursor B cells for HIV with a single immunization. Thus, avoiding scaffold-specific responses augments priming of bnAb precursor B cells, and DNA-VLPs are a promising platform for promoting B cell responses towards challenging subdominant epitopes.Keywords
All Related Versions
- Published version: Science, 391 (6785), eadx6291.
This publication has 94 references indexed in Scilit:
- Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trialeClinicalMedicine, 2022
- DNA Origami Nanostructures Elicit Dose‐Dependent Immunogenicity and Are Nontoxic up to High Doses In VivoSmall, 2022
- Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogensCell Reports, 2022
- Shaping humoral immunity to vaccines through antigen-displaying nanoparticlesCurrent Opinion in Immunology, 2020
- Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial VirusCell, 2019
- Strategies for a multi-stage neutralizing antibody-based HIV vaccineCurrent Opinion in Immunology, 2018
- Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine ImmunogensImmunity, 2018
- The Pathway to a Universal Influenza VaccineImmunity, 2017
- Induction of HIV Neutralizing Antibody Lineages in Mice with Diverse Precursor RepertoiresCell, 2016
- Material properties in complement activationAdvanced Drug Delivery Reviews, 2011